PROTAC BTK/IKZF1/3 Degrader-1
PROTAC BTK/IKZF1/3 Degrader-1 is a selective and orally active BCL6 and IKZF1/3 PROTAC degrader. PROTAC BTK/IKZF1/3 Degrader-1 exhibits antitumor activity. PROTAC BTK/IKZF1/3 Degrader-1 can be used for the research of cancer, such as lymphoma[1]. (Structure Note: Pink: BCL6/IKZF1/3 ligand ; Blue: CRBN ligand (HY-41547) )
Product Specifications
CAS Number
2416130-49-7
UNSPSC
12352005
Target
Btk; IKZF Family; PROTACs
Related Pathways
Immunology/Inflammation; PROTAC; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
CN1CCN(C1=O)[C@@H]2CCCN(C2)C3=CN=C(C(NC4=CC=C(C=C4)C5CCN(CC5)CC6CCN(C6)C7=CC8=C(C(N(C8=O)C9CCC(NC9=O)=O)=O)C=C7)=N3)C(N)=O
Molecular Formula
C43H51N11O6
Molecular Weight
817.94
References & Citations
[1]Jin Y, et al. Modular PROTAC/IMiD Bifunctional Molecule Design for the Degradation of Synergistic Targets in the Treatment of Lymphoma. J Med Chem. 2025 Oct 23;68 (20) :21249-21281.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Cereblon; IKZF1; IKZF3
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC940994-100 1x 100 µL
TNF alpha (J2D10), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680096-100 1x 100 µL
Histone H1 (AE-4), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC682059-100 1x 100 µL
TNFS15 / VEGI (Vascular Endothelial Growth Inhibitor) (rVEGI/1283), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC401830-500 1x 500 µL
CD68 (Macrophage Marker) (LAMP4/1830), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC402659-100 1x 100 µL
Cytokeratin 13 (Non-Keratinized Squamous Epithelial Marker) (KRT13/2213), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details